Ocuphire Pharma Q4 2023 GAAP EPS $(0.210) vs $(0.050) Estimate, Sales $1.700M
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma (OCUP) reported a Q4 2023 GAAP EPS of $(0.210), missing the $(0.050) estimate by 320%. Quarterly sales were $1.700M, missing the $5.349M estimate by 68.22%, and representing a 95.73% decrease from the same period last year.
March 08, 2024 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocuphire Pharma reported significant misses in both EPS and sales for Q4 2023, with a drastic year-over-year sales decrease.
The significant miss in both EPS and sales expectations, coupled with a dramatic year-over-year decrease in sales, is likely to negatively impact investor sentiment and OCUP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100